Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration

Christian Hinderer,1 Nathan Katz,1 Cecilia Dyer,1 Tamara Goode,1 Julia Johansson,1 Peter Bell,1 Laura Richman,1 Elizabeth Buza,1 and James M. Wilson1

Preclinical studies have demonstrated that a single injection of an adeno-associated virus (AAV) vector into the cerebrospinal fluid (CSF) can achieve widespread gene transfer throughout the central nervous system. Successfully translating this approach to humans requires identifying factors that influence AAV distribution in the CSF so that optimal parameters can be replicated in the clinic. In the context of developing a motor neuron-targeted gene therapy for spinal muscular atrophy, we conducted studies in nonhuman primates to evaluate the impact of injection volume on spinal cord transduction after AAV delivery via lumbar puncture. Lumbar injection of an AAVhu68 vector targeted motor neurons throughout the spinal cord, but only in juvenile nonhuman primates administered large injection volumes, equivalent to about half of the total CSF volume. Upon repeating this study with clinically relevant injection volumes and larger animals, we found that lumbar puncture failed to achieve significant transduction of the spinal cord. In contrast, vector administered into the cisterna magna distributed reproducibly throughout the spinal cord in both juvenile and adult animals. These findings highlight the challenges of translating AAV delivery via lumbar puncture to humans and suggest that delivery into the cisterna magna may represent a more feasible alternative.

INTRODUCTION

Adeno-associated virus (AAV)-mediated gene transfer has demonstrated the potential for long-term expression of a transgene in the human brain with an acceptable safety profile.1,3,10 Most evidence of persistent gene transfer has been limited to clinical trials in which the vector was injected directly into the brain parenchyma.1,3 Although this approach is promising for some diseases, intraparenchymal injection is an invasive procedure that results in limited distribution of the vector beyond the injection site, thus making it unsuitable for many applications.3,4 Expanding the potential of AAV gene therapy to new targets will require the identification of capsids and delivery methods that can broadly target cells relevant to each disease. Intravenous AAV delivery offers a noninvasive alternative capable of broad vector distribution. When injected intravenously at high doses, AAV serotype 9 (AAV9) can efficiently transduce primary sensory neurons in the dorsal root ganglia and lower motor neurons in the spinal cord and brainstem.2,7,22 The latter finding led to the development of Zolgensma (onasemnogene abeparvovec-xioi), an intravenous AAV9 gene therapy for the motor neuron disease spinal muscular atrophy (SMA).9 Although delivering AAV9 intravenously can efficiently target motor and sensory neurons that project to the periphery, brain transduction is comparatively modest with this approach.7,9 Clinical applications of intravenous delivery are limited by pre-existing AAV neutralizing antibodies, manufacturing challenges that arise from the large required doses, and systemic toxicity associated with these high doses.7 AAV delivery into the cerebrospinal fluid (CSF) has several advantages: (1) it requires much lower vector doses, (2) it is unaffected by serum neutralizing antibodies,9–11 and (3) it can achieve broad transduction in the brain and spinal cord with a single injection.8–10 Transduction in the brain is diffuse, with only a small percentage of cells expressing the transgene; however, certain cell populations such as the lower motor neurons in the spinal cord are transduced at high frequencies.7

In large-animal studies, transduction of the lower motor neurons has been demonstrated after AAV delivery into the CSF via the lateral cerebral ventricles, cisterna magna, or lumbar cistern.9,12 Injection via lumbar puncture has clear advantages given that this is a widely used approach in clinical practice. However, we and others have previously demonstrated that in contrast with intra-cisterna magna (ICM) injection, lumbar puncture results in a dramatically lower vector distribution to the brain and cervical spinal cord of nonhuman primates (NHPs).8,13,14 Other have also observed limited distribution of AAV from a lumbar puncture in pigs.15 In contrast, Meyer et al.16 demonstrated efficient transduction of the brain and spinal cord after AAV administration to NHPs through a lumbar puncture. The authors showed that transduction could be further increased by placing animals in the Trendelenburg position, but even without this maneuver, transduction was significantly higher than others have observed following lumbar delivery. Meyer et al.16 utilized animals that were substantially smaller and younger than those we employed in our studies, and also mixed the vector with contrast material, resulting in a different formulation and a larger injection volume. We, therefore, explored how these variables impact distribution of...
We tested whether a large injection volume of an AAV vector mixed with contrast material, which resulted in a higher than 10% of motor neurons transduced in the lumbar segment of some animals. Overall transduction was at least 10-fold lower than observed in the prior juvenile study at a similar time point, potentially due to the lower vector dose and injection volume. The low transduction achieved in this study precluded meaningful analysis of safety.

We conducted good laboratory practices (GLP)-compliant toxicology studies in both adult and juvenile rhesus macaques using an AAVhu68 vector expressing the human SMN transgene. The study duration was 28 days. Transgene expression persisted throughout the 6-month study. We euthanized animals 1, 3, or 6 months after vector administration; there was a correlation between peak concentrations and dose volume of 2.5 mL and vector doses of $4.5 \times 10^{12}$ and $1.35 \times 10^{13}$ GC. We euthanized animals 1, 3, or 6 months after vector administration and quantified motor neuron transduction using in situ hybridization (ISH) (Figure 3). Transduction was apparent at all time points, with more than 10% of motor neurons transduced in the lumbar segment of some animals. Overall transduction was at least 10-fold lower than observed in the prior juvenile study at a similar time point, potentially due to the lower vector dose and injection volume. The low transduction achieved in this study precluded meaningful analysis of safety.

### Table 1. Study Design to Compare AAVhu68 Administration via Intracisterna Magna (ICM) Injection or Lumbar Puncture (LP) in Adult and Juvenile Rhesus Macaques

| Age            | Route of Administration | Dose Volume | Number of Animals |
|----------------|-------------------------|-------------|-------------------|
| Adult (3–6 years) | ICM                     | 1 mL        | 3                 |
|                | LP                      | 5 mL        | 4                 |
| Juvenile (12–14 months) | ICM                     | 1 mL        | 3                 |
|                | LP                      | 5 mL        | 2                 |

Macaques were administered $3 \times 10^{15}$ GC of an AAVhu68 vector expressing a human SMN transgene. The study duration was 28 days.

Widespread motor neuron transduction after lumbar AAV injection in juvenile, but not adult, NHPs could be explained by mechanical factors, with the large injection volume coupled with the animal’s small size and CSF volume driving cranial diffusion of the bolus. Alternatively, this finding could be explained by intrinsic biological differences between juvenile and adult animals, such as developmental or anatomic differences that alter vector exposure to target cells. We evaluated these possibilities by administering an AAVhu68 vector via lumbar puncture to animals ranging in age from juvenile (12–14 months) to adult (3 years). A control group was composed of 3-year-old macaques that were treated by ICM injection (Table 2). To determine whether the transduction after lumbar administration was solely due to the large volume administered, we selected a clinically relevant injection volume for this study. We estimated a pediatric intrathecal dosing volume of 5 mL in patients with a total CSF volume of about 100 mL. We then scaled the dose volume to the 13 mL CSF volume of an adult rhesus macaque, resulting in a dose volume of 0.7 mL. Vector administration via lumbar puncture in this volume resulted in minimal spinal cord transduction in all animals, regardless of age (Figure 2). By contrast, ICM injection in adult animals using the same dose and volume transduced an average of 20% of motor neurons at the cervical level and 50% at the lumbar level.

Vector DNA was detectable in CSF and peripheral blood; there was a correlation between peak concentrations in CSF and dose (Figure S1). The concentration of vector DNA in CSF rapidly declined following the first evaluated time point (day 7). Vector genomes in blood declined more slowly, which may be attributable to transduction of peripheral blood cells. At 180 days after administration, vector genomes were undetectable in the blood of all animals and were detectable at low levels (51 copies/12 L) in the CSF of only one animal. Vector genomes were detectable in the urine and feces 5 days after administration; there was a correlation between peak concentrations and dose (Figure S2). Excretion rapidly declined, with most animals exhibiting undetectable levels in both urine and feces by day 28. On day 90, all animals except one had reached undetectable levels of vector DNA in urine. Only one animal in the high-dose cohort had detectable vector DNA in feces (60 copies/µg DNA) on day 90, which was near the limit of detection (50 copies/µg DNA).

Using quantitative PCR, we detected vector genomes at high levels in the brain, spinal cord, dorsal root ganglia, liver, and spleen (see Figure S3), consistent with previous studies of ICM AAV administration. Lower levels of vector DNA were detectable in most tissues sampled, including skeletal muscle, lung, kidney, lymph nodes, and gonads. The quantity of vector genomes detected in CNS tissues was generally dose dependent. Animals euthanized 90 and 180 days
after vector administration exhibited modestly lower vector genome levels in tissues compared with animals euthanized on day 14. This indicates that some vector genomes detected soon after administration do not represent stable transduction. Vector genomes in CNS tissues appeared stable between 90 and 180 days after injection.

Figure 1. Motor Neuron Transduction following AAVhu68 Administration via Intra-cisterna Magna (ICM) Injection or Lumbar Puncture (LP) to Adult and Juvenile NHPs

Adult (3- to 6-year-old) and juvenile (12- to 14-month-old) rhesus macaques were administered $3 \times 10^{13}$ GC of an AAVhu68 vector expressing human SMN from a chicken beta-actin promoter. The vector was injected into the cisterna magna (ICM) in a volume of 1 mL or via LP in a volume of 5 mL. Animals were necropsied 28 days after vector administration. We performed in situ hybridization on spinal cord sections using probes for the human SMN transgene and choline acetyltransferase (A). We quantified the percentage of ChAT$^+$ motor neurons expressing human SMN in spinal cord sections from cervical, thoracic, and lumbar levels (B). Error bars = standard error of the mean (SEM).

We did not detect any dose-limiting toxicity in this study. One animal unexpectedly extended its neck during the ICM injection procedure, resulting in suspected needle penetration of the brainstem. Upon recovery from anesthesia, this animal exhibited mild unilateral weakness. The animal was treated with a short course of prednisone, and the motor deficit resolved within a week of the injection. There were no other clinical abnormalities noted throughout the study. None of the animals exhibited any clinically meaningful changes in hematology, coagulation, or blood and CSF clinical chemistry parameters. One animal treated with the highest vector dose exhibited an asymptomatic self-limited lymphocytic pleocytosis between 28 and 60 days after vector administration (Figure S4).

Similar to previous studies of intrathecal AAV administration, all groups exhibited asymptomatic minimal degeneration of dorsal root ganglia sensory neurons and minimal-to-moderate degeneration of their associated axons in the dorsal white matter tracts of the spinal cord with no clear dose dependence (Figures S5 and S6).10 These findings emerged on day 14 and developed fully by day 90, with no further progression from days 90 to 180.

Neutralizing antibodies to the AAVhu68 capsid were elicited in all vector-treated animals (Figure S7). Interferon-gamma T cell responses to the capsid and transgene product were detectable in peripheral blood, as well as in lymphocytes harvested from the liver, spleen, and bone marrow of some animals (Figure S8). T cell responses to the AAVhu68 capsid occurred in 12 of 27 vector-treated animals, and 15 of 27 exhibited responses to the human SMN protein, with similar frequencies in all dose cohorts. T cell responses were not associated with abnormal clinical or histological findings. T cell responses to the AAVhu68 capsid were detectable prior to treatment in three animals, potentially due to prior infections with other AAV serotypes with conserved T cell epitopes.

| Table 2. Study Design for Evaluating AAVhu68 Administration via Lumbar Puncture to NHPs of Different Ages Using a Clinically Relevant Injection Volume |
|---|---|---|
| Age (years) | Route of Administration | Number of Animals |
| 3 | ICM | 3 |
| 1 | LP | 1 |
| 1.5 | LP | 4 |
| 2 | LP | 3 |
| 3 | LP | 3 |

NHPs were administered $1.5 \times 10^{13}$ GC of an AAVhu68 vector expressing a GFP transgene at a dose of 0.7 mL. The study duration was 21 days.
DISCUSSION

The present studies elucidate key determinants of AAV distribution in CSF and help explain inconsistencies in previous studies. The results of ICM vector administration in NHPs were consistent with our prior studies8,10,17 and other reports from the literature.18 Although we previously reported that lumbar puncture is far less effective than ICM AAV administration in NHPs,8 here we were able to reproduce the successful gene transfer to the spinal cord reported by another group by more closely replicating aspects of their model system and injection method.

Following ICM AAV administration, we consistently observed a lumbar-to-cervical gradient of motor neuron transduction despite the greater distance from the lumbar region to the injection site. We hypothesize that this is related to the anatomy of the lumbar motor neurons, the axons of which may be more exposed to CSF due to the long ventral roots of the lumbar spinal cord. In the present studies, we observed a nonlinear dose-response with markedly lower motor neuron transduction when the dose of the human SMN-expressing vector was decreased from $3 \times 10^{13}$ GC in pilot studies to $1.35 \times 10^{13}$ GC in the toxicology study. This observation may have been partly related to the low sensitivity of ISH for detecting transgene expression, as the study conducted with a GFP reporter gene demonstrated higher overall transduction levels. However, our results suggest that relatively high doses, equivalent to an NHP dose of at least $1.5 \times 10^{13}$ GC, may be required to achieve reliable motor neuron transduction, particularly of the cervical spinal cord. ICM vector administration had a similar safety profile to previous studies;10,17 mild transient pleocytosis and minimal asymptomatic degeneration of sensory neurons in the dorsal root ganglia were the only vector-related adverse effects.

Our findings suggest that AAV delivery via lumbar puncture, although feasible in nonclinical studies, will be challenging to translate to humans. Delivery to the entire spinal cord was possible only when the vector was administered in a large volume in small NHPs, indicating that the distribution of the vector was driven by the spread of the injected bolus rather than by circulation of the vector in CSF. Directly replicating this approach in humans may require administering roughly half of the total CSF volume, which is inconsistent with clinical practice and may cause toxicity from rapid changes in intracranial pressure and CSF electrolytes. Moreover, others have demonstrated that cranial spread of a lumbar bolus is impaired if the dura has been punctured in a previous injection attempt.13 If administering a one-time therapy relies on a lumbar puncture that is always successful on the first attempt, then an unacceptable level of variability may be apparent in clinical outcomes.

These studies were carried out in the context of developing a gene therapy for SMA. Our analysis was therefore focused on the transduction of motor neurons in the spinal cord, although we expect these findings to be broadly applicable to programs that target the spinal cord or brain. The challenges of AAV distribution to the spinal cord following lumbar injection are likely to be further
amplified when the brain is the primary target. Our findings suggest that ICM administration may overcome these delivery challenges.

MATERIALS AND METHODS

Vectors

Vectors were produced by triple transfection of adherent HEK293 cells and purified by ultracentrifugation on an iodixanol gradient (GFP vectors) or by affinity chromatography (SMN vectors) as previously described.5

Animal Procedures

All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. Adult NHPs were 3–8 kg at the time of dosing. One-year-old NHPs were 1.5–3 kg at the time of dosing. NHPs were anesthetized with ketamine and dexmedetomidine for all procedures. ICM injection was performed as previously described.19 Lumbar puncture was performed under fluoroscopic guidance in anesthetized animals. After inserting a spinal needle into the L4–5 or L5–6 space, we confirmed placement by CSF return and/or by injecting up to 1 mL of contrast material (Iohexol 180). After confirming placement, we injected the vector solution by hand at a rate of approximately 2 mL/min. Complete blood counts and serum chemistry panels were evaluated prior to vector administration, then weekly for 1 month and monthly thereafter. CSF (1 mL) was collected by suboccipital puncture. We performed euthanasia with a pentobarbital overdose.

Vector Biodistribution and Pharmacokinetics

We quantified the vector genomes in the blood, CSF, urine, feces, and tissue samples by TaqMan PCR as previously described.10,17

Immunological Assays

Neutralizing antibody assays and ELISPOTs were performed as previously described.5

Histology

We performed tissue fixation and ISH as previously described.7 For quantification of motor neuron transduction, two sections from the cervical, thoracic, and lumbar levels were analyzed. The total number of choline acetyltransferase (ChAT)+ motor neurons and the number of human SMN+/ChAT+ cells was determined for each spinal cord level, and mean percent transduction was calculated. For histopathology, we sectioned and stained formalin-fixed, paraffin-embedded tissues with hematoxylin and eosin according to standard protocols. A
A board-certified veterinary pathologist examined the slides. A second pathologist peer reviewed the slides for the toxicology studies.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.omtm.2020.04.012.

AUTHOR CONTRIBUTIONS
C.H., N.K., and J.M.W. designed experiments; C.H., N.K., C.D., T.G., J.J., P.B., L.R., and E.B. conducted experiments; C.H. and J.M.W. wrote the paper.

CONFLICTS OF INTEREST
J.M.W. is a paid advisor to and holds equity in Scout Bio and Passage Bio; he holds equity in Surmount Bio; he also has a sponsored research agreement with Ultragenyx, Biogen, Jansen, Precision Bio-sciences, Moderna Inc., Scout Bio, Passage Bio, Amicus Therapeutics, and Surmount Bio, which are licensees of Penn technology. J.M.W. is an inventor on patents that have been licensed to various biopharma-ceutical companies and for which he may receive payments. C.H. is an inventor on patents that have been licensed to biopharmaceutical companies and holds equity in Scout Bio.

ACKNOWLEDGMENTS
We would like to thank Erin Bote, Amber Hamilton, Peter Hayashi, Richard Fetterly, Barbara Rice, C. Angelica Medina-Jaszek, Mohamad Nayal, and Yanqing Zhu for technical assistance. We acknowledge the support of the Program for Comparative Medicine, Immunology Core, Vector Core, and Pathology Core of the Gene Therapy Program, University of Pennsylvania. This work was supported by a grant from Biogen.

REFERENCES
1. Mittermeyer, G., Christine, C.W., Rosenbluth, K.H., Baker, S.L., Starr, P., Larson, P., Kaplan, P.L., Forsayeth, J., Aminoff, M.J., and Bankiewicz, K.S. (2012). Long-term evaluation of a phase 1 study of AADAC gene therapy for Parkinson’s disease. Hum. Gene Ther. 23, 377–381.
2. Tardieu, M., Zérah, M., Gougeon, M.L., Ausseil, J., de Bournonville, S., Husson, B., Zafrirous, D., Parenti, G., Bourget, P., Pozier, B., et al. (2017). Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol. 16, 712–720.
3. Kojima, K., Nakajima, T., Taga, N., Miyazaki, A., Kato, M., Matsumoto, A., Ieda, T., Nakamura, K., Kubota, T., Mizukami, H., et al. (2019). Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency. Brain 142, 322–333.
4. Vite, C.H., McGowan, J.C., Niogi, S.N., Passini, M.A., Drobatz, K.J., Haskins, M.E., and Wolfe, J.H. (2005). Effective gene therapy for an inherited CNS disease in a large animal model. Ann. Neurol. 57, 355–364.
5. Hinderer, C., Katz, N., Buza, E.L., Dyer, C., Goode, T., Bell, P., Richman, L.K., and Wilson, J.M. (2018). Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum. Gene Ther. 29, 285–298.
6. Mendell, J.R., Al-Zaidy, S., Sheller, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017). Single-Dose Gene Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 377, 1713–1722.
7. Gurd, B.L., De Guilhem De Latallade, A., Bell, P., Zhu, Y., Yu, H., Wang, B., Bagel, J., Vite, C.H., Sikora, T., Hinderer, C., et al. (2016). Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol. Ther. 24, 206–216.
8. Hinderer, C., Bell, P., Vite, C.H., Louboutin, J.P., Grant, R., Bote, E., Yu, H., Pakenas, B., Hurst, R., and Wilson, J.M. (2014). Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol. Ther. Methods Clin. Dev. 1, 14051.
9. Hinderer, C., Bell, P., Louboutin, J.P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurd, B.L., Bagel, J., O’Donnell, P., et al. (2015). Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates. Mol. Ther. 23, 1298–1307.
10. Hordeaux, J., Hinderer, C., Goode, T., Buza, E.L., Bell, P., Calcedo, R., Richman, L.K., and Wilson, J.M. (2018). Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques. Mol. Ther. Methods Clin. Dev. 10, 68–78.
11. Hautrejot, V., Marcé, S., Ribera, A., García, M., Ruzo, A., Villacampa, P., Ayuso, E., Azón, S., Andaluz, A., Pineda, M., et al. (2013). Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J. Clin. Invest. 123, 3254–3271.
12. Hinderer, C., Bell, P., Katz, N., Vite, C.H., Louboutin, J.P., Bote, E., Yu, H., Zhu, Y., Casal, M.L., Bagel, J., et al. (2018). Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. Hum. Gene Ther. 29, 15–24.
13. Ohno, K., Samaranch, L., Hadaczek, P., Bringas, J.R., Allen, P.C., Sudhakar, V., Stockinger, D.E., Sneekus, C., Campagna, M.V., San Sebastian, W., et al. (2018). Kinetics and MR-based monitoring of AAV9 vector delivery into cerebrospinal fluid of nonhuman primates. Mol. Ther. Methods Clin. Dev. 13, 47–54.
14. Taghian, T., Marosfoi, M.G., Puri, A.S., Cataltepe, O.I., King, R.M., Diffie, E.B., Maguire, A.S., Martin, D.R., Feraud, A., Batista, A.R., Kuchel, T., et al. (2020). A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol. Ther. 28, 411–421.
15. Federici, T., Taub, J.S., Baum, G.R., Gray, S.J., Grieger, J.C., Matthews, K.A., Handy, C.R., Passini, M.A., Samulski, R.J., and Bouls, N.M. (2012). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 19, 852–859.
16. Meyer, K., Ferreira, L., Schmelzer, L., Braun, L., McGovern, V., Lindtke, S., Michels, O., Goveni, A., Fitzgerald, J., Morales, P., Feust, K.D., et al. (2015). Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates. Mol. Ther. 23, 477–487.
17. Hordeaux, J., Hinderer, C., Goode, T., Katz, N., Buza, E.L., Bell, P., Calcedo, R., Richman, L.K., and Wilson, J.M. (2018). Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques. Mol. Ther. Methods Clin. Dev. 10, 79–88.
18. Samaranch, L., Salegio, E.A., San Sebastian, W., Kells, A.P., Bringas, J.R., Forsayeth, J., and Bankiewicz, K.S. (2013). Strong cortical and spinal cord transduction after AAV V and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24, 526–532.
19. Katz, N., Goode, T., Hinderer, C., Hordeaux, J., and Wilson, J.M. (2018). Standardized Method for Intra-Cisterna Magna Delivery Under Fluoroscopic Guidance in Nonhuman Primates. Hum. Gene Ther. Methods 29, 212–219.